LM11A-31 is a small, nonpeptide, monomeric ligand of p75 neutrophin receptor (p75NTR). The compound promotes neuron survival in vitro. PharmatrophiX is developing a modified version of LM11A-31 (LM11A 31 BHS) for the oral treatment of Alzheimer's disease.

RO-31-8220 is a cell-permeable staurosporine analog, that shows potent inhibition of PKC α, PKC βI, PKC βII, PKC γ, and PKC ε. Ro 31-8220 also inhibits MSK1, MAPKAPK1, RSK, GSK3β, and S6K1 with a potency similar to that for PKC. Ro 31-8220 alters cellular protein kinase C localization and potently inhibits the growth of A549 and MCF-7 cells with IC50 of 0.78 μM and 0.897 μM, respectively. RO 31-8220 enhances epinephrine-induced platelet aggregation in catecholamine hypo-responsive platelets by enhancing Akt phosphorylation. Ro 31-8220 significantly decreases apoE secretion from primary human macrophages by inhibiting vesicular transport of apoE to the plasma membrane without significantly affecting apoE mRNA or apoE protein levels.